— Know what they know.
Not Investment Advice
Also trades as: RX.V (TSXV) · $vol 0M

BIOYF OTC

BioSyent Inc.
1W: -2.8% 1M: +0.2% 3M: +11.4% YTD: +23.4% 1Y: +35.0% 3Y: +100.9% 5Y: +112.0%
$11.49
-0.01 (-0.09%)
 
Weekly Expected Move ±6.0%
$10 $11 $11 $12 $13
OTC · Healthcare · Medical - Pharmaceuticals · Tech Score Neutral · Power 60 · $131.4M mcap · 7M float · 0.040% daily turnover · Short 84% of daily vol

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

A-
Oct 02, 2026
DCF
4
ROE
5
ROA
5
D/E
2
P/E
3
P/B
2
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. BIOYF receives an overall rating of A-. Strongest factors: DCF (4/5), ROE (5/5), ROA (5/5). Areas of concern: D/E (2/5), P/B (2/5).
Rating Change History
DateFromTo
2026-08-10 A A-
2026-07-02 A- A
2026-05-27 None ADDED
2026-05-27 EXISTED None
2026-05-14 A A-
2026-04-28 A- A
2026-04-14 None ADDED
2026-04-13 EXISTED None
2026-04-07 None ADDED
2026-04-07 EXISTED None

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ — Grade A+
Profitability
81
Balance Sheet
86
Earnings Quality
79
Growth
74
Value
—
Momentum
96
Safety
—
Cash Flow
87

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
—
—
Piotroski F-Score
5/9
✓ ✓ ✓ ✓ ✗ ✗ ✗ ✗ ✓
Beneish M-Score
-1.52
Possible Manipulator
Ohlson O-Score
-9.41
Bankruptcy prob: 0.0%
Low Risk
Credit Rating
AA-
Score: 82.8/100
Trend: Stable
Earnings Quality
100/100
OCF/NI: 1.23x
Accruals: -4.3%
The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. BIOYF scores 5/9, indicating moderate financial health — some areas of strength offset by weaknesses in others. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. BIOYF's score of -1.52 exceeds the −1.78 red flag threshold — this does not confirm manipulation but indicates the earnings profile resembles past manipulators statistically. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. BIOYF's implied 0.0% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. BIOYF receives an estimated rating of AA- (score: 82.8/100), with a stable trend. The Earnings Quality score measures how well reported earnings are backed by real cash. It evaluates the operating cash flow to net income ratio (OCF/NI ≥ 1.0 means every dollar of earnings is cash-backed) and the accruals ratio (the gap between earnings and cash flow relative to assets — lower is better). BIOYF's score of 100/100 is high — cash flows strongly support reported earnings.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
19.01x
PEG
0.93x
P/S
3.44x
P/B
4.16x
P/FCF
—
P/OCF
—
EV/EBITDA
—
EV/Revenue
—
EV/EBIT
—
EV/FCF
—
Earnings Yield
—
FCF Yield
—
Shareholder Yield
—
Graham Number
$8.68
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. At 19.0x earnings, BIOYF trades at a reasonable valuation. Graham's intrinsic value formula yields $8.68 per share, 32% below the current price.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
0.737
NI / EBT
×
Interest Burden
1.017
EBT / EBIT
×
EBIT Margin
0.236
EBIT / Rev
×
Asset Turnover
1.072
Rev / Assets
×
Equity Multiplier
1.246
Assets / Equity
=
ROE
23.7%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. BIOYF's ROE of 23.7% is driven by Asset Turnover (1.072), indicating efficient use of assets to generate revenue.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate
15.00%
Fair P/E
38.50x
Intrinsic Value
$32.69
Price/Value
—
Margin of Safety
—
Premium
—
Graham's classic formula uses analyst-projected growth to estimate a fair P/E (8.5 + 2g). Our adjusted version replaces that projection with BIOYF's realized 15.0% 3-year EPS CAGR, capped at 15% — demonstrated performance rather than forecasts, held to a rate companies have historically sustained. BIOYF actually compounded EPS at 25.2% over three years; the model uses 15%, the highest rate it will extrapolate — of 4,457 company-quarters that grew faster than 200%, none sustained it over the following seven years. BIOYF trades at a premium to its adjusted intrinsic value of $32.69, suggesting the market is pricing in future growth beyond what historical earnings support. The adjusted fair P/E of 38.5x compares to the current market P/E of 19.0x.

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$11.49
Median 1Y
$12.22
5th Pctile
$6.70
95th Pctile
$22.39
Ann. Volatility
36.3%
25th–75th percentile 5th–95th percentile Median path Historical
All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
ROE 18.0% 21.5% 20.8% 20.8% 19.4% 16.8% 15.4% 16.1% 18.4% 19.0% 20.8% 20.9% 19.8% 20.8% 22.2% 22.6% 22.4% 23.6% 22.3% 23.7% 23.66%
ROA 14.7% 17.8% 17.4% 17.7% 16.1% 14.1% 13.2% 13.7% 15.4% 15.8% 17.9% 17.7% 16.4% 17.5% 18.9% 19.4% 18.5% 19.9% 17.2% 19.0% 18.99%
ROIC 1.0% 1.3% 90.3% 98.6% 88.2% 84.6% 53.9% 72.8% 84.0% 57.6% 51.0% 32.8% 29.3% 32.4% 36.6% 42.0% 46.1% 62.3% 21.8% 23.8% 23.80%
ROCE 21.4% 24.9% 24.2% 24.3% 23.2% 20.2% 18.6% 19.3% 21.1% 21.3% 22.8% 22.8% 22.2% 25.8% 28.0% 29.1% 29.1% 28.4% 26.0% 28.2% 28.20%
Gross Margin 78.6% 80.6% 79.4% 82.4% 82.6% 83.0% 82.3% 81.6% 79.6% 79.6% 78.0% 79.1% 78.3% 81.3% 75.9% 77.7% 75.8% 74.6% 69.6% 65.0% 65.02%
Operating Margin 32.7% 33.1% 30.2% 24.0% 27.3% 18.9% 21.7% 22.0% 31.4% 18.3% 27.0% 21.5% 28.6% 22.8% 27.2% 25.0% 28.1% 24.7% 22.8% 19.8% 19.78%
Net Margin 25.7% 26.0% 22.6% 18.4% 21.4% 16.1% 18.1% 18.6% 26.5% 17.5% 22.9% 17.7% 24.2% 18.3% 21.1% 19.8% 21.9% 20.6% 16.9% 14.3% 14.34%
EBITDA Margin 34.3% 34.6% 32.3% 25.4% 28.8% 21.0% 26.6% 23.3% 32.7% 19.5% 28.5% 22.5% 32.5% 28.4% 30.8% 29.2% 31.6% 27.0% 26.3% 25.1% 25.05%
FCF Margin 16.8% 16.0% 19.0% 21.2% 16.1% 15.9% 12.3% 17.2% 19.9% 8.0% 15.2% 0.9% -0.3% 12.1% 5.7% 18.3% 18.4% 20.8% 27.6% 21.2% 21.18%
OCF Margin 17.4% 16.3% 19.4% 21.9% 17.1% 17.7% 14.5% 18.9% 21.2% 16.5% 23.1% 8.9% 20.8% 25.7% 18.3% 30.3% 19.3% 21.7% 28.3% 21.7% 21.72%
ROE 3Y Avg snapshot only 21.23%
ROE 5Y Avg snapshot only 19.86%
ROA 3Y Avg snapshot only 17.52%
ROIC 3Y Avg snapshot only 21.05%
ROIC Economic snapshot only 19.91%
Cash ROA snapshot only 20.00%
Cash ROIC snapshot only 30.21%
CROIC snapshot only 29.46%
NOPAT Margin snapshot only 17.12%
Pretax Margin snapshot only 24.04%
R&D / Revenue snapshot only 0.37%
SGA / Revenue snapshot only 44.84%
SBC / Revenue snapshot only 0.83%
Valuation
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
P/E Ratio — — — — — — — — — — — — — — — — — — — — 19.011
P/S Ratio — — — — — — — — — — — — — — — — — — — — 3.437
P/B Ratio — — — — — — — — — — — — — — — — — — — — 4.158
P/FCF — — — — — — — — — — — — — — — — — — — — —
P/OCF — — — — — — — — — — — — — — — — — — — — —
EV/EBITDA — — — — — — — — — — — — — — — — — — — — —
EV/Revenue — — — — — — — — — — — — — — — — — — — — —
EV/EBIT — — — — — — — — — — — — — — — — — — — — —
EV/FCF — — — — — — — — — — — — — — — — — — — — —
Earnings Yield — — — — — — — — — — — — — — — — — — — — —
FCF Yield — — — — — — — — — — — — — — — — — — — — —
PEG Ratio snapshot only 0.925
Graham Number snapshot only $8.68
Leverage & Solvency
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Current Ratio 6.30 8.24 8.09 9.29 7.92 6.49 9.02 7.11 6.87 6.48 7.72 6.13 3.92 4.53 4.90 6.07 5.06 5.51 1.89 2.07 2.068
Quick Ratio 5.85 7.70 7.47 8.55 7.00 5.70 7.82 6.29 6.06 5.42 6.37 4.90 3.11 3.54 4.00 5.10 4.23 4.63 1.21 1.29 1.290
Debt/Equity 0.05 0.05 0.05 0.05 0.04 0.04 0.04 0.04 0.04 0.04 0.03 0.03 0.03 0.03 0.03 0.03 0.02 0.02 0.12 0.07 0.069
Net Debt/Equity -0.84 -0.84 -0.79 -0.81 -0.80 -0.82 -0.74 -0.80 -0.81 -0.72 -0.65 -0.46 -0.43 -0.43 -0.46 -0.52 -0.56 -0.67 -0.13 -0.13 -0.127
Debt/Assets 0.04 0.04 0.04 0.04 0.04 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.02 0.03 0.02 0.02 0.02 0.02 0.08 0.05 0.052
Debt/EBITDA 0.22 0.18 0.18 0.17 0.17 0.19 0.20 0.18 0.16 0.15 0.14 0.13 0.12 0.11 0.09 0.08 0.07 0.07 0.40 0.21 0.208
Net Debt/EBITDA -3.51 -3.07 -2.96 -3.02 -3.14 -3.65 -3.59 -3.75 -3.48 -3.09 -2.63 -1.87 -1.79 -1.52 -1.49 -1.62 -1.77 -2.17 -0.43 -0.38 -0.384
Interest Coverage 78.22 96.42 97.42 102.55 100.94 91.06 86.22 90.94 107.05 112.29 123.00 130.27 138.60 156.72 182.67 206.00 228.65 242.73 176.49 123.37 123.369
Equity Multiplier 1.23 1.18 1.18 1.16 1.18 1.21 1.16 1.19 1.20 1.19 1.16 1.17 1.22 1.18 1.19 1.16 1.20 1.19 1.39 1.32 1.319
Cash Ratio snapshot only 0.648
Debt Service Coverage snapshot only 141.817
Cash to Debt snapshot only 2.847
FCF to Debt snapshot only 3.756
Defensive Interval snapshot only 219.2 days
Efficiency & Turnover
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Asset Turnover 0.78 0.81 0.79 0.76 0.73 0.72 0.71 0.74 0.77 0.77 0.83 0.84 0.79 0.85 0.93 0.93 0.90 0.95 0.87 1.07 1.072
Inventory Turnover 3.18 2.80 2.19 2.16 1.57 1.50 1.29 1.45 1.30 1.17 1.28 1.38 1.44 1.30 1.50 1.58 1.64 1.76 1.44 2.13 2.127
Receivables Turnover 9.22 13.98 9.34 9.08 8.66 10.57 7.57 9.70 9.83 11.30 10.80 8.03 9.51 13.49 10.57 8.13 8.95 14.06 8.13 10.85 10.848
Payables Turnover 1.60 1.64 1.79 1.64 1.19 1.17 1.38 1.41 1.24 1.21 1.87 1.70 1.29 1.61 1.97 2.08 1.50 2.03 1.85 3.39 3.390
DSO 40 26 39 40 42 35 48 38 37 32 34 45 38 27 35 45 41 26 45 34 33.6 days
DIO 115 131 167 169 233 243 282 252 280 311 285 264 254 281 244 231 222 208 254 172 171.6 days
DPO 228 222 204 222 308 311 265 258 295 303 196 214 284 227 185 175 243 179 197 108 107.7 days
Cash Conversion Cycle -74 -66 2 -13 -32 -33 65 32 22 41 123 96 9 81 93 100 20 54 102 98 97.6 days
Fixed Asset Turnover snapshot only 35.443
Operating Cycle snapshot only 205.2 days
Cash Velocity snapshot only 6.227
Capital Intensity snapshot only 1.086
Growth (YoY)
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue 22.3% 28.1% 19.2% 5.2% 2.0% -2.4% -3.1% 4.0% 11.2% 13.1% 20.0% 17.9% 12.1% 10.9% 16.5% 16.8% 22.2% 22.9% 20.2% 41.0% 41.00%
Net Income 18.0% 65.5% 54.8% 48.8% 21.1% -13.1% -18.7% -17.1% 1.2% 18.4% 39.8% 34.6% 14.5% 12.5% 10.9% 15.5% 21.5% 23.9% 15.6% 19.6% 19.55%
EPS 18.8% 66.7% 58.0% 51.8% 24.5% -8.5% -16.5% -14.6% 4.8% 21.9% 45.3% 40.2% 19.1% 12.0% 14.3% 18.5% 22.3% 29.8% 14.8% 18.2% 18.21%
FCF -53.6% -31.8% 2.3% 44.6% -2.1% -3.3% -37.0% -15.5% 37.6% -42.9% 47.7% -93.9% -1.0% 68.0% -56.4% 23.0% 89.8% 1.1% 4.8% 63.3% 63.26%
EBITDA 13.4% 51.8% 42.0% 35.6% 15.5% -13.8% -18.9% -18.8% -4.2% 8.2% 23.5% 22.9% 11.0% 21.4% 28.4% 37.1% 42.4% 30.6% 19.3% 26.5% 26.52%
Op. Income 76.6% 1.6% 1.3% 42.1% 17.3% -14.7% -22.4% -22.6% -7.5% 6.8% 30.0% 29.5% 12.3% 17.4% 18.7% 23.6% 32.9% 29.8% 19.6% 25.9% 25.85%
OCF Growth snapshot only 1.08%
Asset Growth snapshot only 39.07%
Equity Growth snapshot only 21.97%
Debt Growth snapshot only 2.33%
Shares Change snapshot only 1.13%
Dividend Growth snapshot only 8.52%
Growth (CAGR)
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue 3Y 8.0% 10.0% 9.4% 9.9% 8.3% 9.2% 6.0% 8.3% 11.5% 12.3% 11.5% 8.9% 8.4% 7.0% 10.7% 12.7% 15.1% 15.5% 18.9% 24.7% 24.75%
Revenue 5Y 10.1% 9.8% 9.5% 7.5% 6.9% 6.1% 5.1% 5.8% 7.4% 8.0% 8.8% 10.2% 9.7% 10.3% 10.7% 11.8% 13.7% 14.0% 14.2% 16.3% 16.28%
EPS 3Y 1.5% 9.5% 8.3% 15.6% 11.6% 11.9% 4.7% 5.0% 15.8% 23.0% 24.2% 22.0% 15.9% 7.7% 11.5% 12.4% 15.2% 21.0% 24.0% 25.2% 25.21%
EPS 5Y 7.6% 11.8% 10.8% 8.9% 8.1% 5.1% 1.8% 2.7% 6.4% 7.9% 9.1% 13.1% 11.7% 13.9% 13.7% 14.0% 17.7% 22.0% 20.3% 20.5% 20.55%
Net Income 3Y -2.6% 3.3% 3.8% 11.6% 8.0% 7.7% 1.4% 2.9% 13.0% 19.4% 20.7% 18.4% 11.9% 5.0% 8.0% 8.8% 12.1% 18.2% 21.5% 23.0% 22.96%
Net Income 5Y 5.0% 7.8% 7.8% 6.0% 4.8% 1.0% -1.5% -0.8% 2.5% 2.5% 4.9% 9.2% 7.8% 10.7% 10.1% 11.1% 15.0% 18.9% 17.7% 18.1% 18.07%
EBITDA 3Y 5.7% 9.8% 7.9% 15.5% 9.4% 6.5% -0.1% 0.1% 7.8% 12.3% 12.5% 10.6% 7.1% 4.2% 8.8% 11.0% 14.8% 19.7% 23.7% 28.7% 28.70%
EBITDA 5Y 6.5% 8.1% 8.1% 6.2% 5.1% 2.5% 1.3% 1.7% 5.5% 4.3% 4.7% 9.0% 6.8% 9.7% 9.6% 11.1% 14.7% 17.6% 16.9% 18.6% 18.61%
Gross Profit 3Y 8.6% 11.0% 10.3% 11.0% 10.2% 11.1% 8.0% 10.4% 13.0% 13.5% 12.3% 9.4% 8.6% 7.0% 10.3% 11.8% 13.3% 12.7% 14.7% 18.3% 18.28%
Gross Profit 5Y 9.7% 9.9% 9.7% 8.3% 8.0% 7.4% 6.7% 7.2% 8.6% 9.0% 9.4% 10.6% 10.1% 10.8% 10.9% 11.9% 13.4% 13.4% 13.0% 13.8% 13.84%
Op. Income 3Y 1.8% 8.7% 7.5% 16.3% 10.3% 7.5% -0.4% 11.8% 24.2% 33.1% 32.1% 12.5% 6.8% 2.3% 6.1% 7.4% 11.3% 17.6% 22.6% 26.3% 26.30%
Op. Income 5Y 5.4% 7.3% 7.4% 5.8% 4.7% 0.4% -1.4% -1.1% 2.7% 3.2% 4.6% 9.5% 6.9% 9.3% 8.8% 17.5% 23.4% 29.1% 26.7% 17.3% 17.25%
FCF 3Y -8.9% -7.5% 1.4% 11.2% 35.4% 1.9% -12.7% -10.3% -14.5% -27.8% -1.6% -57.9% — -2.5% -26.0% 7.4% 20.3% 26.4% 55.4% 33.7% 33.68%
FCF 5Y 8.8% 2.8% 2.7% 5.1% -3.8% -5.6% -10.7% -4.6% 0.4% -15.2% -0.6% -41.1% — 0.3% -15.6% 1.1% -4.6% 5.9% 19.3% 23.9% 23.91%
OCF 3Y -10.1% -9.4% -1.2% 9.7% 2.4% 1.2% -10.8% -9.6% -6.3% -9.0% 11.9% -10.7% 15.0% 24.3% 8.4% 25.5% 19.7% 23.6% 48.7% 30.7% 30.74%
OCF 5Y 6.9% 1.2% 1.5% 3.2% -4.6% -5.4% -9.5% -4.5% 0.1% -3.7% 5.9% -8.1% 10.2% 13.5% 4.6% 10.3% 0.5% 6.3% 19.2% 23.5% 23.53%
Assets 3Y 8.3% 6.0% 8.1% 10.6% 9.1% 9.3% 7.6% 9.0% 9.1% 7.3% 6.4% 6.5% 6.8% 3.6% 4.1% 4.6% 7.0% 6.9% 17.4% 15.3% 15.25%
Assets 5Y 16.6% 14.1% 13.8% 11.8% 11.1% 10.0% 8.4% 6.9% 7.1% 5.9% 5.9% 8.1% 8.7% 6.0% 6.5% 7.3% 8.4% 8.0% 13.5% 12.0% 11.99%
Equity 3Y 4.5% 4.6% 5.9% 9.7% 9.1% 9.0% 9.2% 9.6% 9.8% 9.1% 7.6% 7.1% 7.2% 3.5% 4.0% 4.7% 6.5% 7.5% 10.5% 11.5% 11.52%
Book Value 3Y 8.9% 10.9% 10.5% 13.6% 12.8% 13.2% 12.7% 11.9% 12.4% 12.4% 10.7% 10.4% 11.0% 6.2% 7.3% 8.1% 9.5% 10.1% 12.8% 13.6% 13.56%
Dividend 3Y — — — — — — — — — 62.9% 30.0% 14.5% 5.5% 5.5% 6.1% 6.1% 5.5% 5.2% 5.1% 5.0% 5.04%
Growth Quality
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue Stability 0.88 0.79 0.93 0.92 0.86 0.75 0.83 0.92 0.88 0.85 0.88 0.95 0.97 0.94 0.88 0.93 0.95 0.95 0.92 0.79 0.792
Earnings Stability 0.10 0.06 0.09 0.11 0.15 0.02 0.00 0.07 0.34 0.23 0.27 0.60 0.85 0.76 0.71 0.76 0.95 0.85 0.87 0.88 0.876
Margin Stability 0.99 0.99 0.99 0.98 0.98 0.98 0.97 0.97 0.98 0.98 0.97 0.98 0.98 0.98 0.98 0.98 0.98 0.97 0.96 0.94 0.942
Rev. Growth Consistency 1.00 1.00 1.00 1.00 1.00 0.00 0.00 1.00 1.00 0.50 0.50 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
Earn. Growth Consistency 0.50 0.50 0.50 0.50 1.00 0.00 0.00 0.00 1.00 0.50 0.50 0.50 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
FCF Positive Streak 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 0 1 1 1 1
Earnings Persistence 0.93 0.50 0.50 0.80 0.92 0.95 0.93 0.93 1.00 0.93 0.84 0.86 0.94 0.95 0.96 0.94 0.91 0.90 0.94 0.92 0.922
Earnings Smoothness 0.84 0.51 0.57 0.61 0.81 0.86 0.79 0.81 0.99 0.83 0.67 0.70 0.87 0.88 0.90 0.86 0.81 0.79 0.86 0.82 0.822
ROE Trend -0.01 0.04 0.03 0.02 0.02 -0.01 -0.02 -0.01 0.00 0.00 0.03 0.02 0.01 0.03 0.04 0.04 0.03 0.02 -0.01 0.00 0.005
Gross Margin Trend 0.00 0.01 0.01 0.02 0.03 0.03 0.04 0.03 0.02 0.00 -0.01 -0.02 -0.03 -0.02 -0.03 -0.03 -0.03 -0.04 -0.05 -0.08 -0.084
FCF Margin Trend -0.09 -0.09 -0.03 -0.02 -0.14 -0.07 -0.08 -0.01 0.03 -0.08 -0.00 -0.18 -0.18 0.00 -0.08 0.09 0.09 0.11 0.17 0.12 0.116
Sustainable Growth Rate 18.0% 21.5% 20.8% 20.8% 19.4% 15.3% 12.5% 11.7% 12.7% 13.4% 15.0% 15.1% 14.1% 14.9% 16.2% 16.7% 16.7% 17.7% 16.6% 18.0% 17.98%
Internal Growth Rate 17.2% 21.6% 21.1% 21.5% 19.2% 14.7% 11.9% 11.1% 11.9% 12.5% 14.9% 14.6% 13.2% 14.3% 16.0% 16.8% 16.0% 17.5% 14.6% 16.9% 16.87%
Cash Flow Quality
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
OCF/Net Income 0.93 0.74 0.88 0.94 0.77 0.91 0.78 1.02 1.05 0.81 1.07 0.42 1.01 1.24 0.89 1.45 0.94 1.04 1.44 1.23 1.225
FCF/OCF 0.96 0.98 0.98 0.97 0.94 0.90 0.85 0.91 0.94 0.49 0.66 0.10 -0.01 0.47 0.31 0.60 0.95 0.96 0.97 0.98 0.975
FCF/Net Income snapshot only 1.195
OCF/EBITDA snapshot only 0.800
CapEx/Revenue 0.6% 0.3% 0.4% 0.8% 1.0% 1.9% 2.1% 1.7% 1.3% 8.5% 7.9% 8.0% 21.1% 13.5% 12.6% 12.0% 0.9% 0.9% 0.7% 0.5% 0.54%
CapEx/Depreciation snapshot only 0.152
Accruals Ratio 0.01 0.05 0.02 0.01 0.04 0.01 0.03 -0.00 -0.01 0.03 -0.01 0.10 -0.00 -0.04 0.02 -0.09 0.01 -0.01 -0.08 -0.04 -0.043
Sloan Accruals snapshot only -0.246
Cash Flow Adequacy snapshot only 4.532
Earnings Quality Score snapshot only 1.000
Dividends & Buybacks
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Dividend Yield — — — — — — — — — — — — — — — — — — — — 1.29%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.04 $0.08 $0.12 $0.16 $0.16 $0.16 $0.17 $0.18 $0.18 $0.18 $0.19 $0.19 $0.20 $0.20 $0.20 $0.21
Payout Ratio 0.0% 0.0% 0.0% 0.0% 0.0% 8.9% 19.2% 27.3% 31.0% 29.6% 27.7% 27.8% 28.7% 28.6% 27.1% 26.2% 25.5% 25.0% 25.5% 24.0% 24.01%
FCF Payout Ratio 0.0% 0.0% 0.0% 0.0% 0.0% 10.9% 28.6% 29.4% 31.4% 75.7% 39.1% 6.6% — 49.0% 97.5% 29.9% 28.4% 25.2% 18.2% 20.1% 20.09%
Total Payout Ratio 21.8% 29.4% 40.8% 46.5% 64.8% 76.4% 76.1% 96.4% 84.8% 80.0% 86.7% 70.7% 61.7% 99.8% 85.1% 77.0% 74.5% 36.4% 50.4% 64.2% 64.19%
Div. Increase Streak — — — — — 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1
Chowder Number — — — — — — — — — — — — — — — — — — — — —
Buyback Yield — — — — — — — — — — — — — — — — — — — — —
Net Buyback Yield — — — — — — — — — — — — — — — — — — — — —
Total Shareholder Return — — — — — — — — — — — — — — — — — — — — —
DuPont Factors
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Tax Burden (NI/EBT) 0.74 0.75 0.75 0.75 0.74 0.73 0.73 0.73 0.75 0.76 0.76 0.75 0.76 0.74 0.74 0.74 0.73 0.75 0.74 0.74 0.737
Interest Burden (EBT/EBIT) 1.01 1.02 1.02 1.03 1.04 1.06 1.06 1.09 1.10 1.11 1.15 1.14 1.10 1.06 1.02 1.00 1.00 1.00 1.01 1.02 1.017
EBIT Margin 0.25 0.29 0.29 0.30 0.29 0.25 0.24 0.23 0.25 0.24 0.25 0.25 0.25 0.26 0.27 0.28 0.28 0.28 0.26 0.24 0.236
Asset Turnover 0.78 0.81 0.79 0.76 0.73 0.72 0.71 0.74 0.77 0.77 0.83 0.84 0.79 0.85 0.93 0.93 0.90 0.95 0.87 1.07 1.072
Equity Multiplier 1.23 1.21 1.19 1.18 1.21 1.20 1.17 1.18 1.19 1.20 1.16 1.18 1.21 1.19 1.17 1.16 1.21 1.19 1.30 1.25 1.246
Per Share
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
EPS (Diluted TTM) $0.39 $0.49 $0.49 $0.51 $0.49 $0.45 $0.41 $0.43 $0.52 $0.55 $0.59 $0.61 $0.61 $0.62 $0.68 $0.72 $0.75 $0.80 $0.78 $0.85 $0.85
Book Value/Share $2.36 $2.48 $2.53 $2.59 $2.64 $2.76 $2.71 $2.69 $2.87 $2.96 $2.91 $3.00 $3.22 $2.97 $3.13 $3.27 $3.47 $3.68 $3.89 $3.94 $4.02
Tangible Book/Share $2.29 $2.41 $2.46 $2.51 $2.57 $2.66 $2.61 $2.59 $2.77 $2.87 $2.82 $2.92 $2.73 $2.54 $2.70 $2.85 $3.04 $3.25 $1.68 $1.66 $1.66
Revenue/Share $2.11 $2.25 $2.23 $2.18 $2.22 $2.31 $2.22 $2.34 $2.55 $2.69 $2.77 $2.87 $2.98 $2.97 $3.32 $3.44 $3.67 $3.82 $3.97 $4.79 $4.89
FCF/Share $0.35 $0.36 $0.42 $0.46 $0.36 $0.37 $0.27 $0.40 $0.51 $0.22 $0.42 $0.03 $-0.01 $0.36 $0.19 $0.63 $0.67 $0.79 $1.09 $1.01 $1.04
OCF/Share $0.37 $0.37 $0.43 $0.48 $0.38 $0.41 $0.32 $0.44 $0.54 $0.44 $0.64 $0.25 $0.62 $0.76 $0.61 $1.04 $0.71 $0.83 $1.12 $1.04 $1.06
Cash/Share $2.11 $2.21 $2.12 $2.21 $2.22 $2.37 $2.13 $2.27 $2.43 $2.23 $2.00 $1.48 $1.47 $1.35 $1.51 $1.77 $2.03 $2.54 $0.94 $0.77 $0.78
EBITDA/Share $0.57 $0.68 $0.67 $0.69 $0.67 $0.62 $0.56 $0.58 $0.67 $0.69 $0.72 $0.74 $0.77 $0.83 $0.95 $1.04 $1.11 $1.14 $1.13 $1.30 $1.30
Debt/Share $0.12 $0.12 $0.12 $0.12 $0.12 $0.12 $0.11 $0.11 $0.10 $0.10 $0.10 $0.10 $0.09 $0.09 $0.09 $0.08 $0.08 $0.07 $0.45 $0.27 $0.27
Net Debt/Share $-1.98 $-2.09 $-2.00 $-2.09 $-2.11 $-2.26 $-2.02 $-2.17 $-2.32 $-2.13 $-1.90 $-1.38 $-1.38 $-1.26 $-1.43 $-1.69 $-1.96 $-2.47 $-0.49 $-0.50 $-0.50
Academic Models
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Altman Z-Score — — — — — — — — — — — — — — — — — — — — —
Piotroski F-Score 7 8 8 7 7 5 6 6 6 6 7 6 7 7 6 7 7 8 3 5 5
Beneish M-Score -2.12 -1.96 -1.34 -2.25 -2.29 -1.93 -2.37 -2.41 -2.29 -1.72 -1.67 0.66 1.51 -1.70 -1.15 -2.85 -2.17 -2.19 -2.07 -1.52 -1.518
Ohlson O-Score snapshot only -9.414
ROIC (Greenblatt) snapshot only 80.66%
Net-Net WC snapshot only $1.20
EVA snapshot only $5529460.91
Credit
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Credit Rating snapshot only AA-
Credit Score 82.75 82.75 82.75 82.75 82.75 82.75 82.75 82.75 82.75 82.75 82.75 83.20 79.60 82.75 82.75 82.75 82.75 82.75 82.75 82.75 82.750
Credit Grade snapshot only 4
Credit Trend snapshot only 0.000
Implied Spread (bps) snapshot only 100.000

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms